Viking is developing VK2735, its dual GIP/GLP-1 receptor agonist, in injectable form -- like current marketed weight ...

Jeremy Swayman vastly underperformed after a combative contract negotiation bled into the preseason. Charlie McAvoy and ...

Explore Xcel Energy Inc.'s 6.25% Junior Subordinated Notes: strong fundamentals but limited upside. Click for more on XEL and ...

Has NBA offense peaked? Have defenses finally caught on to the league's 3-point-heavy modern offenses? Well, no. This was actually a pretty natural balance to what we saw in the 2023-24 season, when ...

This is one of the most common mistakes we see at Teamhood. Teams dive into execution too fast, then lose weeks rewriting plans when stakeholders realize they all had different expectations. Clear ...

Lastly, China and other US competitors are slowly but surely reducing their exposure to the US dollar, and what better way ...